HC Wainwright reaffirmed their buy rating on shares of Metagenomi (NASDAQ:MGX - Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.
Other equities analysts also recently issued reports about the company. BMO Capital Markets cut their price objective on Metagenomi from $22.00 to $17.00 and set an "outperform" rating on the stock in a report on Thursday, August 15th. Chardan Capital restated a "buy" rating and issued a $15.00 price target on shares of Metagenomi in a report on Wednesday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, Metagenomi presently has a consensus rating of "Moderate Buy" and an average price target of $15.50.
Check Out Our Latest Report on Metagenomi
Metagenomi Trading Up 10.0 %
Shares of MGX stock traded up $0.17 on Thursday, reaching $1.82. 629,393 shares of the stock were exchanged, compared to its average volume of 188,160. The firm has a 50 day moving average of $2.10 and a two-hundred day moving average of $3.75. Metagenomi has a 1-year low of $1.61 and a 1-year high of $12.74.
Hedge Funds Weigh In On Metagenomi
Institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers purchased a new position in shares of Metagenomi during the 2nd quarter valued at approximately $26,000. BNP Paribas Financial Markets boosted its stake in Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company's stock valued at $28,000 after acquiring an additional 7,256 shares during the last quarter. Virtu Financial LLC acquired a new position in Metagenomi during the 3rd quarter worth $33,000. XTX Topco Ltd bought a new stake in shares of Metagenomi in the 2nd quarter worth about $66,000. Finally, Resolute Advisors LLC raised its stake in shares of Metagenomi by 165.0% in the 2nd quarter. Resolute Advisors LLC now owns 26,500 shares of the company's stock valued at $108,000 after purchasing an additional 16,500 shares in the last quarter.
Metagenomi Company Profile
(
Get Free Report)
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
See Also
Before you consider Metagenomi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metagenomi wasn't on the list.
While Metagenomi currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
